News Releases

January 5, 2018 at 8:00 AM EST

Summary Toggle Molecular Templates Provides Corporate Update and Outlines 2018 Milestones

Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017 Updated MT-3724 Clinical Results Expected in 1H18 At Least Two New MTEM Products to Enter the Clinic in 2018 AUSTIN, Texas , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.
November 21, 2017 at 4:01 PM EST

Summary Toggle Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference

AUSTIN, Texas , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
November 14, 2017 at 4:15 PM EST

Summary Toggle Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer

Company Also Added Key Members to the Senior Management Team Barbara Ruskin J.D . Ph.D. Appointed SVP, General Counsel and Chief Patent Officer Nenad Sarapa M.D. M.S . Appointed SVP of Clinical Development Conrad Jordaan Appointed SVP of Finance and Corporate Controller AUSTIN, Texas , Nov.
November 14, 2017 at 4:01 PM EST

Summary Toggle Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results

Completed Merger with Threshold Pharmaceuticals in August Recent Equity Financings of $60 Million Provide Cash Runway into late 2019 MT-3724 Advancing in Clinical Trials with New Data Expected in 1H18 AUSTIN, Texas , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.
October 24, 2017 at 8:52 AM EDT

Summary Toggle Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)

- Maximum Tolerated Dose of MT-3724 Identified AUSTIN, Texas , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), today announced the dosing of the first
October 6, 2017 at 8:00 AM EDT

Summary Toggle Molecular Templates to Present at the 2017 BIO Investor Forum

AUSTIN, Texas , Oct. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
September 22, 2017 at 1:54 PM EDT

Summary Toggle Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

AUSTIN, Texas , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
September 6, 2017 at 2:17 PM EDT

Summary Toggle Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference

AUSTIN, Texas , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
August 30, 2017 at 8:30 AM EDT

Summary Toggle Molecular Templates to Ring NASDAQ Closing Bell
August 14, 2017 at 8:00 AM EDT

Summary Toggle Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference

AUSTIN, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM ) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in

News Releases

News Releases

About Molecular Templates

Recent Posts